Health technology company, Twinn.health has announced the launch of its artificial intelligence (AI)-driven imaging platform aiming to revolutionise early detection of age-related diseases. The platform leverages AI algorithms to analyse MRI data, providing risk assessments for common causes of frailty. The platform was built on over a decade of research from Imperial College London and detects causes of frailty up to 10 years earlier than current assessment methods.
"Twinn.health's AI-powered platform offers a game-changing solution for age-related disease detection and management," said Dr. Wareed Alenaini, Founder and CEO of Twinn.health. "Our mission is to unlock the true potential of imaging data to improve health outcomes and prevent multiple diseases with a single MRI scan."
The platform is the first of its kind to use MRI data for risk assessment in the context of frailty. It has been validated through retrospective clinical studies involving 400 patients and 3 radiologists. Features of the Twinn.health platform include, heatmaps highlighting areas of concern and adipose tissue, AI-generated risk scores reflecting a patient's risk for highlighted diseases, and AI reports summarising key findings and analysis.
The company is currently raising a pre-Series A round to progress its metabolic disease AI through FDA approval and expand its disease pipeline.
Click here to read the original news story